Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Atoltivimab/maftivimab/odesivimab, sold under the brand name INMAZEB, is a fixed-dose combination of three monoclonal antibodies for the treatment of ebola caused by Zaire ebolavirus. It was developed by Regeneron Pharmaceuticals and contains three human monoclonal antibodies, atoltivimab, maftivimab, and odesivimab-ebgn.
History & Applications
Explore the main themes, entities and connections around Atoltivimab/maftivimab/odesivimab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
atoltivimab maftivimab mab114 ebola regn-eb3 odesivimab trial treatment virus zaire monoclonal outbreak infection drug ebolavirus patients participants antibodies zmapp drc
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Atoltivimab/maftivimab/odesivimab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | ATC code | None | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Atoltivimab | Monoclonal antibody | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | CAS Number | 2500649-90-9 | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | KEGG | D11922 | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Legal status | US: ℞-only | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | License data | US DailyMed: Inmazeb | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Maftivimab | Monoclonal antibody | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Odesivimab | Monoclonal antibody | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Other names | REGN-EB3 | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Routes of administration | Intravenous | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | Trade names | Inmazeb | 1.00 | infobox |
| Atoltivimab/maftivimab/odesivimab | is a | first FDA-approved treatment for Zaire ebolavirus | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.